Abrysvo (Respiratory Syncytial Virus Vaccine, Bivalent)

Abrysvo is a vaccine that helps protect against RSV, a virus that can cause serious lung infections. It is given as a shot into the arm muscle to older adults, adults at higher risk, and pregnant people late in pregnancy so their newborn is protected. It teaches the immune system to make antibodies against the virus.

Brand names:Abrysvo
Medication

What people taking Abrysvo (Respiratory Syncytial Virus Vaccine, Bivalent) report

Every report comes from a Lived member, sent anonymously.

NameHow it went

No reports yet

Add what worked for you with the search bar below

About Abrysvo (Respiratory Syncytial Virus Vaccine, Bivalent)

What It's For

Abrysvo is Pfizer's vaccine against respiratory syncytial virus (RSV), a common virus that usually causes a cold but can lead to pneumonia and other lower respiratory tract infections (infections of the airways and lungs). Those serious infections are most likely in young babies and in older adults or people with chronic heart, lung or other medical conditions. The vaccine has two quite different uses. Given during pregnancy, at 32 through 36 weeks, it protects the baby from severe RSV illness from birth through the first 6 months of life. Given to adults, it protects the person who receives it. The US Food and Drug Administration (FDA) has approved it for adults 60 and older and for adults 18 through 59 who are at increased risk because of a chronic medical condition. The Centers for Disease Control and Prevention (CDC) recommendation is narrower: an RSV vaccine for everyone 75 and older, and for adults 50 to 74 who are at increased risk of severe RSV. Abrysvo is the only RSV vaccine the CDC recommends during pregnancy. Parents can instead protect a newborn with a long-acting antibody shot given to the baby, either nirsevimab (Beyfortus) or clesrovimab (Enflonsia). Neither approach is preferred over the other, and most babies need only one of them. For older adults, Arexvy (GSK) and mResvia (Moderna) are other approved RSV vaccines.

How It Works

RSV uses a surface protein called the F (fusion) protein to break into the cells lining the airways. Abrysvo contains a stabilized version of this protein, in the shape it takes before it attacks a cell, from both main strains of the virus, RSV A and RSV B. That is what bivalent means here. The immune system learns to recognize the protein and makes antibodies that can block the virus before it causes a deeper lung infection. The vaccine is made from laboratory-produced copies of this protein, not from the virus itself, so it cannot cause an RSV infection. In pregnancy, the benefit goes mainly to the baby. The pregnant person's antibodies cross the placenta, so the baby is born already carrying protection during the months when RSV is most dangerous for them. That transfer takes time, which is why the timing of the shot matters.

Dosage & Administration

Abrysvo is a single 0.5 mL injection into a muscle, usually in the upper arm. A pharmacist, nurse or clinician mixes the powder with the supplied liquid just before giving it. It can be given at the same visit as other recommended vaccines; in pregnancy that includes the Tdap (tetanus, diphtheria and whooping cough), flu and COVID-19 vaccines. In pregnancy, the shot is given between 32 and 36 weeks only, because a possible link to preterm birth was seen when it was given earlier in studies. In most of the continental US, the CDC recommends giving it from September through January so the baby is born during or just before RSV season. Places with different RSV seasons, such as Alaska, Hawaii and southern Florida, follow local timing. The CDC does not currently recommend another dose in a later pregnancy; babies born after a later pregnancy are protected with an infant antibody shot instead. For adults, current guidance is one dose. Adults who have already had any RSV vaccine should not get another one, and it is not a yearly shot like the flu vaccine. Anyone with a moderate or severe illness, with or without fever, usually waits until they recover.

Side Effects

The most common effects are pain where the shot was given, tiredness, headache, muscle aches and, especially in pregnancy, nausea. In the pregnancy trial, about 4 in 10 people had arm pain and about 3 in 10 had a headache. In adults 60 and older these effects were less common, each affecting roughly 1 in 10 people. They usually pass within a few days. Some people feel faint right after an injection, which is why sitting down for a short time afterward is sensible. Guillain-Barré syndrome (GBS) is a rare condition in which the immune system attacks the nerves, causing weakness that can spread. A study of Medicare patients found a higher rate of GBS in the 42 days (six weeks) after Abrysvo, estimated at about 9 extra cases per million doses in people 65 and older. The study could not prove the vaccine caused it, but the FDA added a warning in 2025. The first signs are usually weakness or tingling in the legs. Contact a clinician promptly if this develops in the weeks after vaccination; weakness that spreads quickly or affects breathing needs emergency care. Allergic reactions, including hives and rarely anaphylaxis (a severe whole-body allergic reaction), have been reported. Vaccination sites keep treatment ready for this.

Interactions & Warnings

Do not get Abrysvo after a severe allergic reaction to a previous dose or to any of its ingredients. Tell the person giving the shot about past vaccine reactions and about any history of Guillain-Barré syndrome. In pregnancy, the trials showed slightly more preterm births in the vaccine group than the placebo group (5.7% versus 4.7%). The evidence cannot show whether the vaccine caused this, but the FDA limited its use to 32 to 36 weeks to avoid the possible risk from earlier doses. Pre-eclampsia (a pregnancy condition with high blood pressure that can affect organs) was also slightly more frequent, 1.8% versus 1.4%. People at high risk of preterm birth were largely left out of the studies. This trade-off is a reasonable reason to discuss the infant antibody shot as the alternative. People with a weakened immune system, including those taking medicines that suppress immunity such as chemotherapy, high-dose steroids or transplant drugs, may make fewer antibodies and be less protected. In pregnancy, this can also mean less protection reaches the baby, and the baby's clinician may recommend an antibody shot as well.

What to Expect

For a baby, the timing of the shot matters: if the baby is born less than 14 days after the shot, the CDC recommends the baby also receive nirsevimab, because there may not have been time for enough antibodies to cross the placenta. Babies born before 34 weeks also get the antibody shot. Let the delivery team and the baby's doctor know the date of the vaccine. In the main pregnancy trial, babies of vaccinated mothers had about 82% fewer cases of severe RSV illness in their first 3 months and about 69% fewer through 6 months, compared with babies of mothers given a placebo. Protection is highest early and fades over the following months, so a baby can still catch RSV, though it is less likely to become serious. In adults 60 and older, the vaccine cut RSV lung infections by about two thirds in the first season, and by more for the more severe infections with several symptoms. Approval in adults under 60 was based on antibody levels rather than a trial counting infections. No vaccine protects everyone, so an RSV infection after vaccination is still possible, and ordinary care for colds and breathing illnesses still applies.

Questions to Ask Your Doctor

  1. 1.Given my age and health conditions, would an RSV vaccine benefit me, and is Abrysvo the right one?
  2. 2.Should I get the vaccine during this pregnancy, or would an antibody shot for the baby after birth suit us better?
  3. 3.Does my pregnancy history or risk of preterm birth change which option you recommend?
  4. 4.If my baby arrives within two weeks of the shot, who will arrange the infant antibody shot?
  5. 5.Does my medical history, including any past Guillain-Barré syndrome or a weakened immune system, change the decision?

Last reviewed • Oct 2026

Educational content, not medical advice.